Agomelatine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Agomelatine: From Major Depressive Disorder to Melancholia
One-Sentence Summary
Agomelatine (Valdoxan®) is a novel antidepressant combining MT1/MT2 melatonin receptor agonism with 5-HT2C serotonin receptor antagonism, approved in Europe for Major Depressive Disorder (MDD). The TxGNN model predicts it may be particularly effective for Melancholia — a severe MDD subtype defined by profound anhedonia, early-morning awakening, and circadian dysregulation — with a mechanistic rationale that aligns closely with the drug's known pharmacology. Currently, 0 clinical trials and 20 publications support this direction, including multiple Tier 1 network meta-analyses.
Report scope note: The highest-evidence predicted indication (Melancholia, Evidence Level L1, Proceed with Guardrails) is used as the primary focus of this report. The top TxGNN-scored prediction — benign paroxysmal torticollis of infancy (score 99.96%) — is classified as L5/Hold with no supporting evidence, and is addressed briefly under indication triage below.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major Depressive Disorder (EMA-approved; not registered in Singapore) |
| Predicted New Indication | Melancholia |
| TxGNN Prediction Score | 99.88% |
| Evidence Level | L1 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Agomelatine acts through two synergistic pharmacological mechanisms. As an MT1/MT2 melatonin receptor agonist, it re-synchronizes disrupted circadian rhythms and restores normal sleep architecture — particularly suppressed slow-wave and REM sleep. As a 5-HT2C antagonist, it disinhibits dopamine and norepinephrine release in the prefrontal cortex, enhancing motivation, reward processing, and cognitive function. This combination is unique among antidepressants, representing the first class to extend beyond monoaminergic neurotransmission.
Melancholia is a severe MDD subtype (ICD-10: F32.2–F32.3) distinguished by its core features: profound anhedonia (loss of capacity for pleasure), marked diurnal mood variation, early-morning awakening, psychomotor disturbance, and pervasive circadian rhythm disintegration. These hallmarks map directly onto agomelatine's two targets: the melatonergic pathway addresses the circadian and sleep-architecture disruptions, while 5-HT2C blockade targets the dopaminergic deficit underlying anhedonia — a feature specifically highlighted in recent literature (Serretti, 2025; Serretti, 2023).
The EMA has already approved agomelatine for MDD in adults, which by clinical definition includes melancholic presentations. The body of evidence — encompassing Cipriani et al.'s 2018 Lancet network meta-analysis of 21 antidepressants, two additional maintenance-phase systematic reviews, and multiple agomelatine-specific meta-analyses — consistently confirms its efficacy and favorable tolerability. The convergence of mechanistic alignment, phenotypic overlap, and high-quality published evidence renders the TxGNN prediction biologically and clinically well-founded.
Clinical Trial Evidence
Currently no clinical trials are registered specifically for Agomelatine in Melancholia.
Agomelatine has been extensively evaluated in Major Depressive Disorder trials (which include melancholic presentations), but no trials are indexed under the isolated "melancholia" indication on ClinicalTrials.gov. Researchers may search ClinicalTrials.gov directly using terms "agomelatine" + "major depressive disorder" for broader trial coverage.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29477251 | 2018 | Network Meta-Analysis (RCT) | The Lancet | Among 21 antidepressants for acute MDD, agomelatine showed superior acceptability (low dropout rate) and significant efficacy vs. placebo; landmark reference for positioning agomelatine in depression treatment |
| 36253442 | 2023 | Systematic Review / Meta-Analysis | Molecular Psychiatry | In MDD maintenance phase, agomelatine demonstrated efficacy in relapse prevention based on double-blind RCTs with enrichment design |
| 39684343 | 2024 | Systematic Review / Meta-Analysis | Int J Mol Sci | Agomelatine efficacy and safety confirmed in depressed patients with comorbid diabetes; metabolically neutral profile advantageous in complex patients |
| 37960759 | 2023 | Meta-Analysis | Medicine | Systematic meta-analysis confirms agomelatine's overall efficacy and safety in depressive disorder treatment |
| 41135546 | 2025 | Systematic Review | The Lancet | Network meta-analysis comparing antidepressant physiological side-effects; agomelatine demonstrated a favorable cardiometabolic profile relative to other agents |
| 40129874 | 2025 | Review | PCN Reports | Agomelatine explicitly identified as one of a small group of agents with promising anti-anhedonic effects — directly targeting melancholia's defining symptom |
| 37424409 | 2023 | Review | Clin Psychopharmacol Neurosci | Anhedonia framed as a transdiagnostic dimension linked to suicidality and inflammation; agomelatine's dopaminergic disinhibition mechanism is mechanistically relevant |
| 22876742 | 2012 | Review | Expert Opin Investig Drugs | SCN-pineal-melatonin axis dysfunction proposed as causal in MDD; agomelatine's MT1/MT2 agonism directly restores circadian integrity disrupted in melancholia |
| 32568567 | 2020 | Review | Expert Opin Drug Discov | Comprehensive preclinical development review; agomelatine is the first antidepressant acting beyond monoaminergic neurotransmission, with unique mechanism relevant to circadian-driven depression |
| 31206585 | 2019 | Cochrane Systematic Review | Cochrane Database Syst Rev | Agomelatine evaluated for preventing seasonal affective disorder (SAD) — a circadian-linked depressive syndrome phenotypically overlapping with melancholic features |
Singapore Market Information
Agomelatine is currently not registered in Singapore. No product licenses or marketing authorizations are on record with the Health Sciences Authority (HSA).
Agomelatine is commercially available in Europe as Valdoxan® and Thymanax® (Servier), with EMA approval for Major Depressive Disorder in adults. Any use or registration in Singapore would require a new HSA application. Clinicians should refer to the EMA Summary of Product Characteristics (SmPC) for the most current prescribing information.
Safety Considerations
Please refer to the package insert for safety information.
Practical note for evaluators: The EMA-approved SmPC for Valdoxan® includes a Black Box–equivalent warning for hepatotoxicity, requiring liver function tests (ALT/AST) before treatment initiation and at weeks 3, 6, 12, and 24. This monitoring requirement should be factored into any Singapore-specific implementation plan. Full contraindications (including hepatic impairment and concurrent CYP1A2 inhibitors such as fluvoxamine) should be reviewed directly from the EMA SmPC, as formal safety data was not available in this evidence pack.
Indication Triage Summary
The following table summarizes all 10 predicted indications to provide full transparency on the TxGNN output:
| Rank | Indication | TxGNN Score | Evidence Level | Recommendation | Notes |
|---|---|---|---|---|---|
| 1 | Benign paroxysmal torticollis of infancy | 99.96% | L5 | Hold | No mechanistic link; likely false positive |
| 2 | Agoraphobia | 99.95% | L4 | Research Question | Theoretical 5-HT2C/amygdala rationale; no direct evidence |
| 3 | Neurotic disorder | 99.90% | L4 | Hold | Diagnosis too broad; insufficient specificity |
| 4 | Melancholia | 99.88% | L1 | Proceed with Guardrails | Primary report focus — strongest evidence |
| 5 | Neurotic depression | 99.88% | L2 | Proceed with Guardrails | Overlaps dysthymia/mild MDD; mechanistic rationale supported |
| 6 | Ohdo syndrome and variants | 99.87% | L5 | Hold | Genetic neurodevelopmental disease; no mechanistic link |
| 7 | Dysthymic disorder | 99.86% | L3 | Research Question | Chronic low mood; theoretical support but no agomelatine-specific trials |
| 8 | Ligneous conjunctivitis | 99.83% | L5 | Hold | Plasminogen deficiency disease; no biological intersection |
| 9 | Blepharophimosis–intellectual disability (Ohdo type) | 99.82% | L5 | Hold | Genetic subtype of Ohdo syndrome; same as rank 6 |
| 10 | Keppen-Lubinsky syndrome | 99.81% | L5 | Hold | Ultra-rare KCNK4 channelopathy; no relevant connection |
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Agomelatine's dual MT1/MT2 agonism and 5-HT2C antagonism mechanistically targets the two defining features of melancholia — circadian rhythm disruption and anhedonia — and the EMA has already approved the drug for MDD (which includes melancholic subtypes). A robust body of Tier 1 evidence (network meta-analyses in The Lancet, Cochrane review, multiple systematic reviews) establishes efficacy and tolerability, justifying an L1 evidence classification and a cautious-proceed recommendation.
To proceed, the following is needed:
- Regulatory pathway: File for Singapore HSA registration; agomelatine has no current local authorization
- Safety documentation: Obtain complete Singapore-specific prescribing information including contraindications, warnings, and drug interactions (currently absent from evidence pack — data gap DG001)
- MOA documentation: Formally retrieve and document mechanism of action from DrugBank (data gap DG002) to support regulatory submission
- Hepatotoxicity monitoring protocol: Establish a local liver function monitoring plan aligned with EMA requirements (ALT/AST at baseline, weeks 3, 6, 12, 24)
- Melancholia-specific evidence: Consider designing or supporting a clinical trial explicitly enrolling melancholic MDD patients to generate indication-specific evidence in the Asian/Singapore population
- Drug interaction review: Evaluate CYP1A2 inhibitor co-prescribing patterns in the local population (fluvoxamine, ciprofloxacin are contraindicated with agomelatine per EMA SmPC)
This report is generated for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before therapeutic application. 2026-04-04
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.